• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.

作者信息

Pietrantonio F, Garassino M C, Torri V, de Braud F

机构信息

Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

出版信息

Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8.

DOI:10.1093/annonc/mds332
PMID:22875835
Abstract
摘要

相似文献

1
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.随机德国AIO研究KRK-0306中KRAS突变肿瘤患者亚组分析：FOLFIRI联合西妥昔单抗对比FOLFIRI联合贝伐单抗作为转移性结直肠癌患者一线治疗的疗效
Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8.
2
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.FOLFIRI 联合西妥昔单抗与 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者：KRAS 突变肿瘤患者的随机德国 AIO 研究 KRK-0306 亚组分析。
Ann Oncol. 2012 Jul;23(7):1693-9. doi: 10.1093/annonc/mdr571. Epub 2012 Jan 4.
3
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.FOLFIRI 联合西妥昔单抗对比 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌（FIRE-3）：这项随机、开放标签的 3 期临床试验最终 RAS 野生型亚组中肿瘤动态的事后分析。
Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27.
4
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.在德国环境下，针对 K-ras 野生型结直肠癌患者肝内初始不可切除转移的靶向治疗药物西妥昔单抗的成本效益分析。
Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.
5
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.BRAF和RAS突变对FOLFIRI联合西妥昔单抗与FOLFIRI联合贝伐单抗一线疗效的影响：FIRE-3（AIO KRK-0306）研究分析
Eur J Cancer. 2017 Jul;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29.
6
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).CEA 反应与 KRAS 外显子 2 野生型和扩展 RAS 野生型转移性结直肠癌患者的肿瘤反应和生存相关，这些患者接受一线 FOLFIRI 加西妥昔单抗或贝伐珠单抗治疗（FIRE-3 试验）。
Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27.
7
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.FOLFIRI 联合西妥昔单抗与 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者（FIRE-3）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.
8
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.雷莫芦单抗联合 FOLFIRI 二线治疗用于贝伐珠单抗、奥沙利铂和氟嘧啶一线治疗后进展的转移性结直肠癌患者：一项随机、双盲、多中心、III 期研究（RAISE）。
Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.
9
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.KRAS 密码子 12 突变型肿瘤的特定突变对接受西妥昔单抗一线治疗的转移性结直肠癌患者治疗效果的影响：三项试验的汇总分析。
Oncology. 2012;83(5):241-7. doi: 10.1159/000339534. Epub 2012 Aug 29.
10
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.FOLFIRI + 西妥昔单抗与 FOLFIRI + 贝伐珠单抗一线治疗德国野生型转移性结直肠癌的成本效果分析：FIRE-3（AIO KRK-0306）研究数据。
J Med Econ. 2020 May;23(5):448-455. doi: 10.1080/13696998.2019.1709848. Epub 2020 Jan 17.

引用本文的文献

1
A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer.西妥昔单抗和帕尼单抗等表皮生长因子受体（EGFR）抑制剂单药及联合治疗转移性结直肠癌的临床试验综述
Avicenna J Med Biotechnol. 2015 Oct-Dec;7(4):134-44.